GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Renal, Bladder, Prostate | National | Completed
TEST
Osellus Dev
Start Date: January 31, 2023
Bladder | ON | Recruiting
D9450C00001
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
Start Date: June 7, 2022

Other Canadian Centers:

1. The Ottawa Hospital:                                                                                                                    

2. Mount Sinai Hospital (Toronto): 

Bladder | ON | Recruiting, by invitation only
ROSY-D
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D)
Start Date: April 19, 2022

Contact: Southlake Regional Health Centre (Newmarket): 905-895-4521 (Canadian Site)

Sponsor: AstraZeneca

Other Canadian Centres: Southlake Regional Health Centre (Newmarket): 905-895-4521

Renal | AB, BC, ON, QC | Recruiting
MK-6482-012
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012).
Merck Sharp & Dohme LLC
Start Date: April 14, 2021

Contact: 1-888-577-8839

NCT #: NCT04736706

Sponsor: Merck Sharp & Dohme LLC & Eisai

Other Canadian Centers:

Tom Baker Cancer Centre (Calgary): Contact 403-521-3266
BC Cancer - Vancouver Center (Vancouver): Contact 604-877-6000
Juravinski Cancer Centre (Hamilton): Contact 905-387-9495 x 63123
Sunnybrook Research Institute (Toronto): Contact: 416-480-5847
CHU de Quebec Universite Laval (Quebec City): 418-525-4444

Prostate | AB, BC, MB, NB, NL, ON, QC, SK | Recruiting
PR22 (ANZUP 1801)
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer
Dr. M. Tamin Niazi (JGH)
Start Date: March 31, 2020

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Test
  • Test
  • Test
Renal | BC, NB, ON, QC | Active, not recruiting
CheckMate 914
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney.
Start Date: July 7, 2017
Renal | MB, NB, ON, QC, SK | Active, not recruiting
MK-3475-564/ KEYNOTE-564
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy.
Start Date: June 9, 2017
Testes | MB, NL, NS, ON, QC | Recruiting
AGCT1531
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Dr. A. L Frazier
Start Date: May 8, 2017

Sponsored by Children's Oncology Group in Collaboration with the National Cancer Institute (NCI).

More Info

Prostate | ON, QC | Recruiting
PR19
A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
Dr. Eric Vigneault (CHUQ) & Dr. Gerar Morton (Odette Cancer Centre)
Start Date: November 4, 2016
Testes | National | Planned
NO DATE

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy